z-logo
open-access-imgOpen Access
Combination of hormone replacement therapy with natural metabolite preparations (glycine and limontar) in the treatment of menopausal syndrome
Author(s) -
Alexander Dreval,
Larisa Marchenkova,
R. S. Tshienin,
B I Minchenko,
Г. А. Оноприенко,
V. I. Shumsky,
И. А. Комиссарова,
Ya. R. Narcissov
Publication year - 1999
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl11785
Subject(s) - medicine , osteopenia , endocrinology , osteoporosis , menopause , hormone replacement therapy (female to male) , physiology , bone mineral , testosterone (patch)
Clinical efficacy of two drugs, natural metabolites glycine and limontar, alone and in combination with substitute hormone therapy (SHT), is studied in patients with menopausal disorders. The clinical efficacy was assessed from the time course of neurovegetative, psychoemotional, and urogenital menopausal symptoms and from changes in mineral compactness of bone tissue and biochemical parameters of calcium-phosphorus metabolism and osseous metabolism. The results confirmed the efficacy of SHT in all types of climacteric disorders (neurovegetative, psychoemotional, urogenital, and in postmenopausal osteopenia). Combination of SHT with glycine and limontar did not affect the time course of the neurovegetative syndrome in general, but facilitated the arrest of arterial pressure differences and giddiness by estrogens. Moreover, glycine and limontar effectively relieve headaches. Combination of glycine with limontar is effective in asthenoneurotic syndrome in general and in individual psychoemotional symptoms: irritability, labile spirits, sleep disorders. In general asthenia and urogenital disorders glycine and limontar accelerated the clinical effect of SHT and in case of low spirits and decreased libido extend the spectrum of positive effects of SHT. The combination of glycine with limontar had no positive effect on the mineral compactness of bones. Combination of both drugs with SHT attenuated the process of bone formation, increased calcium excretion with the urine, and increased the hypocalcemic effect, and hence, they should not be prescribed in postmenopausal osteopenia or osteoporosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here